Journal article
Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial
AS Cheung, R Hoermann, J Zhu, D Lim Joon, JD Zajac, M Grossmann
Therapeutic Advances in Endocrinology and Metabolism | SAGE PUBLICATIONS LTD | Published : 2021
Abstract
Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity via its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resulting in increased insulin resistance. In a randomised controlled trial (RCT) of zoledronic acid versus placebo in men commencing extended-duration ADT, we aimed to examine the effects on fat mass and glucose metabolism. We hypothesised that zoledronic acid, which reduces osteocalcin concentrations, would worsen ADT-induced insulin resistance. Methods: This was a prespecified secondary analysis of..
View full abstractRelated Projects (4)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by an Australian Government National Health and Medical Research Council (NHMRC) Project Grant (#1062073). Ada Cheung was supported by a NHMRC Medical and Dental Postgraduate Research Scholarship (#1017233), NHMRC Early Career Fellowship (#1143333) and an Endocrine Society of Australia Postdoctoral Award. Mathis Grossmann was supported by a NHMRC Career Development Fellowship (#1024139).